|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Intent-to-Treat Analysis of Double-Blind Methamphetamine Study Confirms Hythiam, Inc.'s PROMETA Treatment Program Showed Statistically Significant Reduction in Cravings Compared to Placebo
6/19/2008 9:04:08 AM
LOS ANGELES--(BUSINESS WIRE)--Hythiam, Inc. (NASDAQ:HYTM) announced that the results of the first double-blind, placebo-controlled study utilizing Hythiam’s PROMETA® Treatment Program (PROMETA) were presented yesterday at the College on Problems of Drug Dependence (CPDD) conference in San Juan, Puerto Rico, by addiction expert Harold C. Urschel, III, M.D., M.M.A. The 30-day study focused on evaluating the impact of PROMETA on cravings during the treatment of methamphetamine dependence, and was designed as a follow-up to Dr. Urschel’s 90-day open-label study on the effects of PROMETA in treatment-seeking, methamphetamine-dependent individuals.
|
|
|
|
|
|
|
|
|
|
|